Sorry, you need to enable JavaScript to visit this website.


DC Health

DC Agency Top Menu

-A +A
Bookmark and Share

March 09, 2022- Emergency Use Authorization Revisions to Evusheld Dosing

Friday, March 11, 2022

On February 24, 2022, The U.S. Food and Drug Administration revised the emergency use authorization(EUA) for Evusheld (tixagevimab co-packaged with cilgavimab) to change the initial dose for the authorized use as pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric
patients. Based on the most recent information and data available, Evusheld may be less active against certain Omicron subvariants. The dosing regimen was revised because available data indicate that a higher dose of Evusheld may be more likely to prevent infection by the COVID-19 Omicron subvariants
BA.1 and BA.1.1 than the originally authorized Evusheld dose. This health notice provides guidance on the revised dosing criteria for the COVID-19 theraputic, Evusheld.